» Articles » PMID: 22773955

The CRM1 Nuclear Export Protein in Normal Development and Disease

Overview
Specialty Biochemistry
Date 2012 Jul 10
PMID 22773955
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

CRM1 (Chromosomal Maintenance 1, also known as Exportin 1) is the major mammalian export protein that facilitates the transport of large macromolecules including RNA and protein across the nuclear membrane to the cytoplasm. The gene encoding CRM1 was originally identified in yeast as required to maintain higher order chromosome structure. In mammalian cells, CRM1 was found to bind several nuclear pore proteins hence its role in nuclear-cytosolic transport was discovered. In addition to nuclear-cytosolic transport, CRM1 also plays a role in centrosome duplication and spindle assembly, especially in response to DNA damage. The crystal structure of CRM1 suggests a complex protein that binds the Ran protein bound to GTP, allowing for a conformational change that facilitates binding to different cargo proteins through a nuclear export signal (NES). Included in the cadre of cargo are multiple tumor suppressor and oncoproteins as p53, BRCA1, Survivin, NPM, and APC, which function in the nucleus to regulate transcription or aid in chromosomal assembly and movement. An imbalance in the cytosolic level of these proteins has been observed in cancer cells, resulting in either inactivation (tumor suppressor) or an excess of anti-apoptotic activity (oncoprotein). Thus, the concept of inhibiting CRM1 has been explored as a potential therapeutic intervention. Indeed, inhibition of CRM1 by a variety of small molecules that interfere with cargo-NES binding results in cancer cell death. Whether all of these proteins together are responsible for this phenotype or whether specific proteins are required for this effect is unclear at this time.

Citing Articles

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.

Alhalabi O, Gouda M, Milton D, Momin H, Yilmaz B, Stephen B Cancer Med. 2025; 14(4):e70280.

PMID: 39945382 PMC: 11822648. DOI: 10.1002/cam4.70280.


Itaconate and its derivatives as anti-pathogenic agents.

Al Akiki Dit Al Mazraani R, Malys N, Maliene V RSC Adv. 2025; 15(6):4408-4420.

PMID: 39931396 PMC: 11808480. DOI: 10.1039/d4ra08298b.


Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?.

Sokolova V, Gruber R, Pammer L, Kocher F, Klieser E, Amann A Mol Biol Rep. 2024; 52(1):87.

PMID: 39729162 PMC: 11680630. DOI: 10.1007/s11033-024-10169-5.


The Potential of Nuclear Pore Complexes in Cancer Therapy.

Zaitsava H, Gachowska M, Bartoszewska E, Kmiecik A, Kulbacka J Molecules. 2024; 29(20).

PMID: 39459201 PMC: 11510365. DOI: 10.3390/molecules29204832.


Development of a UPLC-MS/MS method for quantifying KPT-335 (Verdinexor) in feline plasma for a study of PK.

Yang Y, Qiu J, Kong J, Cao Y, Liu Y, Chen S Front Vet Sci. 2024; 11:1438295.

PMID: 39132444 PMC: 11310113. DOI: 10.3389/fvets.2024.1438295.


References
1.
Look A, Kirstein M, Valentine M, Raimondi S, Cohen K, Carroll A . The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene. 1996; 12(2):265-75. View

2.
Burgess A, Faux M, Layton M, Ramsay R . Wnt signaling and colon tumorigenesis--a view from the periphery. Exp Cell Res. 2011; 317(19):2748-58. DOI: 10.1016/j.yexcr.2011.08.010. View

3.
Lohrum M, Woods D, Ludwig R, Balint E, Vousden K . C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol. 2001; 21(24):8521-32. PMC: 100015. DOI: 10.1128/MCB.21.24.8521-8532.2001. View

4.
Nohara T, RYO T, Iwamoto S, Gon G, Tanigawa N . Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology. 2001; 60(1):94-100. DOI: 10.1159/000055303. View

5.
Wente S, Rout M . The nuclear pore complex and nuclear transport. Cold Spring Harb Perspect Biol. 2010; 2(10):a000562. PMC: 2944363. DOI: 10.1101/cshperspect.a000562. View